NEW YORK (GenomeWeb News) —Illumina today said it has closed its $600 million acquisition of Solexa.
"We are excited to join the two companies, creating the only company with genome-scale technology for genotyping, gene expression, and sequencing, the three cornerstones of modern genetic analysis," Illumina CEO Jay Flatley said in a statement.
"With Solexa's recent technical achievements we look forward to the rapid commercialization of our next-generation sequencing platform," he added.
In connection with the merger, Illumina has increased the size of its board from eight to 10 members, adding Blaine Bowman and Roy Whitfield, both of whom were Solexa directors.
Illumina will report its fourth quarter financial results on Feb. 1.